Cover Image
市場調查報告書

Halozyme Therapeutics, Inc.:產品平台分析

Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224710
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Halozyme Therapeutics, Inc.:產品平台分析 Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 36 Pages
簡介

Halozyme Therapeutics, Inc. ha,是癌症和皮膚科,糖尿病,藥物輸送針對市場的創新的提供產品的積蓄,對新的重組的人型酵素的開發與商品化投入力量的生物科技企業。該公司的產品系列,被網羅象hiaruronidaze一樣的人型酵素群,及細胞外基質產生影響的補充的酵素的智慧財產權左右。

本報告提供Halozyme Therapeutics, Inc.提供著的治療藥開發平台的現狀及各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Halozyme Therapeutics, Inc.的基本資料

  • Halozyme Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Halozyme Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Halozyme Therapeutics, Inc.:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Halozyme Therapeutics, Inc.:開發中產品概況

  • 臨床實驗階段有的開發中產品
    • 第二階段有的產品/聯合治療模式
    • 第一階段有的產品/聯合治療模式
  • 初期階段有的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Halozyme Therapeutics, Inc.:藥物簡介

  • Analog Insulin-PH20
  • HTI-501
  • PEGPH-20

Halozyme Therapeutics, Inc.:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Halozyme Therapeutics, Inc.:最近的開發平台趨勢

Halozyme Therapeutics, Inc.:暫停中的計劃

Halozyme Therapeutics, Inc.:企業發表

Halozyme Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07143CDB

Summary

Global Markets Direct's, 'Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Halozyme Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Halozyme Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Halozyme Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Halozyme Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Halozyme Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Halozyme Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Halozyme Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Halozyme Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Halozyme Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Halozyme Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Halozyme Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Halozyme Therapeutics, Inc. Snapshot
    • Halozyme Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Halozyme Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Halozyme Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Halozyme Therapeutics, Inc. - Pipeline Products Glance
    • Halozyme Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Halozyme Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Halozyme Therapeutics, Inc. - Drug Profiles
    • Analog Insulin-PH20
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HTI-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEGPH-20
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Halozyme Therapeutics, Inc. - Pipeline Analysis
    • Halozyme Therapeutics, Inc. - Pipeline Products by Target
    • Halozyme Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Halozyme Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Halozyme Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Halozyme Therapeutics, Inc. - Recent Pipeline Updates
  • Halozyme Therapeutics, Inc. - Dormant Projects
  • Halozyme Therapeutics, Inc. - Company Statement
  • Halozyme Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Halozyme Therapeutics, Inc., Key Information
  • Halozyme Therapeutics, Inc., Key Facts
  • Halozyme Therapeutics, Inc. - Pipeline by Indication, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Halozyme Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Halozyme Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Halozyme Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Halozyme Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015
  • Halozyme Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Halozyme Therapeutics, Inc. - Phase II, 2015
  • Halozyme Therapeutics, Inc. - Phase I, 2015
  • Halozyme Therapeutics, Inc. - Preclinical, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Target, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Halozyme Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Halozyme Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Halozyme Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Halozyme Therapeutics, Inc., Subsidiaries

List of Figures

  • Halozyme Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Halozyme Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Halozyme Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Halozyme Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Halozyme Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top